In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Celsion (CLSN – Research Report), with a price target of $16.00. The company’s shares opened today at $2.05.
According to TipRanks, Bodnar is a 3-star analyst with an average return of 2.1% and a 42.42% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Celsion, Context Therapeutics, and Dice Therapeutics.
Celsion has an analyst consensus of Moderate Buy, with a price target consensus of $16.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on Celsion’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $125 thousand and a GAAP net loss of $6.04 million. In comparison, last year the company earned a revenue of $125 thousand and had a GAAP net loss of $5.45 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celsion Corp . engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
Read More on CLSN:
- Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
- Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13
- Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
- Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
